Impacts of receiving pharmacogenomic (PGx) testing on study outcomes at 12-month follow-up in high risk versus low risk PGx recipients (n=434, Low Risk PGx, n=41 High Risk PGx)
| Outcomes | Baseline | Follow-up | Mean Difference Follow-up–Baseline | Statistic/effect | p Value | |||
|---|---|---|---|---|---|---|---|---|
| Low PGx Risk | High PGx Risk | Low PGx Risk | High PGx Risk | Low PGx Risk | High PGx Risk | |||
| Primary outcomes | ||||||||
| Visits to physician (Mean, SD) | 3.3 (3.4) | 4.4 (3.2) | 3.4 (3.5) | 6.4 (5.6) | 0.20 (3.3) | 2.0 (4.9) | η2=0.017 | 0.006* |
| Follow-up state anxiety (Mean, SD) | 35.5 (9.7) | 33.3 (8.4) | 35.0 (10.4) | 33.2 (9.0) | −0.48 (7.0) | −0.10 (6.6) | η2<0.0005 | 0.99* |
| Share results with physician (% yes) | NA | NA | 42.3 | 65.8 | NA | NA | OR=2.08 | 0.04† |
| Secondary outcomes | ||||||||
| Physician ordered additional tests (% yes)‡ | NA | NA | 26.9 | 29.6 | NA | NA | OR=1.51 | 0.40† |
| Visits to other healthcare provider (Mean, SD) | NA | NA | 1.4 (3.4) | 1.5 (2.2) | NA | NA | η2<0.0005 | 0.74§ |
| Share results with genetic counselor (% Yes) | NA | NA | 17.1 | 34.1 | NA | NA | OR=2.32 | 0.02† |
| Follow-up test-related distress (Mean, SD) | NA | NA | 1.0 (4.1) | 1.6 (5.0) | NA | NA | η2=0.001 | 0.41§ |
*Repeated measures analysis of variance, time by group interaction.
†Logistic regression, effect of group (PGx recipient coded 1, non-recipient coded 0).
‡Analysis included the subset of individuals who reported sharing their results with a physician (n=209).
§Analysis of covariance, effect of group.